CervoMed (NASDAQ:CRVO) Earns “Buy” Rating from HC Wainwright

CervoMed (NASDAQ:CRVO)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. HC Wainwright also issued estimates for CervoMed’s Q4 2026 earnings at ($0.59) EPS, FY2026 earnings at ($2.70) EPS, Q1 2027 earnings at ($0.51) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.50) EPS, Q4 2027 earnings at ($0.53) EPS and FY2027 earnings at ($1.99) EPS.

Several other research firms have also weighed in on CRVO. D. Boral Capital reaffirmed a “buy” rating and issued a $31.00 target price on shares of CervoMed in a report on Wednesday, April 22nd. Chardan Capital lifted their price target on shares of CervoMed from $15.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. Roth Capital set a $9.00 price target on shares of CervoMed in a report on Monday, May 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of CervoMed in a research report on Monday, April 20th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.60.

CervoMed Price Performance

Shares of CRVO stock opened at $3.14 on Wednesday. The stock’s fifty day simple moving average is $3.31 and its 200 day simple moving average is $4.41. The firm has a market cap of $42.48 million, a price-to-earnings ratio of -0.96 and a beta of -0.68. CervoMed has a one year low of $2.13 and a one year high of $13.13.

CervoMed (NASDAQ:CRVO) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.86) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.04. CervoMed had a negative return on equity of 136.08% and a negative net margin of 672.80%. On average, research analysts anticipate that CervoMed will post -2.84 earnings per share for the current year.

Insider Transactions at CervoMed

In other CervoMed news, Director Joshua S. Boger acquired 955,414 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was purchased at an average price of $3.14 per share, for a total transaction of $2,999,999.96. Following the transaction, the director owned 1,795,865 shares in the company, valued at $5,639,016.10. This trade represents a 113.68% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 35.80% of the company’s stock.

Institutional Trading of CervoMed

Large investors have recently made changes to their positions in the business. Rhumbline Advisers increased its stake in shares of CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock valued at $53,000 after buying an additional 1,526 shares in the last quarter. XTX Topco Ltd acquired a new position in CervoMed during the 4th quarter worth about $81,000. Jane Street Group LLC acquired a new position in CervoMed during the 4th quarter worth about $88,000. Marshall Wace LLP bought a new stake in CervoMed during the 2nd quarter worth about $76,000. Finally, Dimensional Fund Advisors LP bought a new stake in CervoMed during the 4th quarter worth about $110,000. Institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.